Price$19.30-0.61 (-3.06%)
2025-10-202026-01-23
News · 26 weeks10%
2025-12-142026-06-07
Mix090d
No activity.
Latest news
25 items- PRDefiance ETFs Announces Closure of Select FundsNEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tidal Financial Group and Defiance ETFs today announced their decision to close and liquidate eight exchange-traded funds listed on the Nasdaq: Defiance Leveraged Long + Income PLTR ETF (NASDAQ:PLT)Defiance Leveraged Long + Income SMCI ETF (NASDAQ:SMCC)Defiance Leveraged Long + Income HOOD ETF (NASDAQ:HOOI)Defiance Leveraged Long + Income Ethereum ETF (NASDAQ:ETHI)Defiance Leveraged Long + Income AMD ETF (NASDAQ:AMDU)Defiance Leveraged Long + Income HIMS ETF (NASDAQ:HIMY)Defiance Trillion Dollar Club Index ETF (NASDAQ:TRIL)Defiance Daily Target 2X Short LLY ETF (LLYZ) The Board of Trustees of Tidal Trust II approved this action as part of Defia
- PRDefiance Launches $TRIL – The Trillion Dollar Club ETF: The New "Magnificent 7" of Global MarketsNEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Defiance ETFs, a leader in innovative and first-mover exchange-traded funds, today announced the launch of the Defiance Trillion Dollar Club Index ETF (NASDAQ:TRIL), the first ETF designed to give investors exposure to the exclusive group of companies and crypto assets with market capitalizations above $1 trillion (the "Trillion Dollar Assets"). TRIL seeks to track the performance, before fees and expenses, of the BITA Trillion Dollar Club Index, which includes U.S. exchange-listed companies and U.S.-listed crypto ETFs tied to assets valued at $1 trillion or greater. As of September 15, 2025, the trillion-dollar club included Tesla, Alphabet,
- NEWSWho's Who At The Benzinga Psychedelics Capital Conference? Check Out These CEOs & Meet Them In PersonThis year’s edition of the Benzinga Psychedelics Capital Conference, THE place to be for those interested or already involved in the space, will take place on April 13, following our established Cannabis Capital Conference (CCC), at the Fontainebleau Miami Beach Hotel in Florida. Together with superb keynote speakers and specialized leaders in psychedelics advisory, let’s take a glimpse at some of the leaders of well-established psychedelics companies on the speakers’ list of this exciting event. Najla Guthrie, CEO Of Wellbeing Digital Sciences And A Scientific Visionary Guthrie is CEO of one of the busiest companies among publicly-traded psychedelics firms. We’re also glad to say she’
- NEWS10 Psychedelics CEOs To Pay Attention To In 2022By Javier Hasse and Aaron Bry. 2020 and 2021 were defining years for the burgeoning psychedelics industry. In 2021 alone, more than $730 million were invested into various psychedelic companies, both private and public. Businesses around the globe are researching and developing new drugs based on psychedelic properties to support a whole host of conditions. Some of the most active companies to watch boast impressive CEOs to keep an eye on in 2022. Here are a few to watch closely: Amy Emerson - MAPS Public Benefit Corporation (MAPS PBC) Amy Emerson is the Chief Executive Officer at the MAPS Public Benefit Corporation (MAPS PBC), a wholly-owned subsidiary of the Multidisciplinary Associati
- PROncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of DirectorsMr. Parsons served as the Chief Financial Officer of Trillium Therapeutics, which was recently acquired by Pfizer Inc. SAN DIEGO and CALGARY, AB, June 17, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Thursday, June 16, 2022. A total of 40.43% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting. Additionally, James T. Parsons was elected to the Oncolytics Biotech Board of Directors. Leonard (Leon) Kruimer did not stand for re-election as a director at the AGM. Mr. Parsons commented, "Oncolytics' clini
- SECSEC Form 15-12B filed by Trillium Therapeutics Inc.15-12B - Trillium Therapeutics Inc. (0001616212) (Filer)
- SECSEC Form EFFECT filed by Trillium Therapeutics Inc.EFFECT - Trillium Therapeutics Inc. (0001616212) (Filer)
- SECSEC Form EFFECT filed by Trillium Therapeutics Inc.EFFECT - Trillium Therapeutics Inc. (0001616212) (Filer)
- INSIDERSEC Form 4: Walker Paul Edward returned 5,736,363 shares to the company4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
- INSIDERSEC Form 4 filed by Pucci Paolo4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
- INSIDERSEC Form 4 filed by Myers Scott Dunseth4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
- INSIDERSEC Form 4: Harrison Rosemary returned 75 shares to the company, closing all direct ownership in the company4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
- INSIDERSEC Form 4 filed by Beshar Luke M4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
- INSIDERSEC Form 4 filed by Parsons James T.4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
- INSIDERSEC Form 4 filed by Kamarck Michael E.4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
- INSIDERSEC Form 4 filed by Looker Benjamin4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
- INSIDERSEC Form 4 filed by Mackey Catherine J4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
- INSIDERSEC Form 4 filed by Bruns Ingmar4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
- INSIDERSEC Form 4 filed by Petrova Penka4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
- INSIDERSEC Form 4 filed by Uger Robert4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
- INSIDERSEC Form 4 filed by Tayton-Martin Helen Katrina4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
- INSIDERSEC Form 4 filed by Skvarka Jan4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
- 13D/GSEC Form SC 13D/A filed by Trillium Therapeutics Inc. (Amendment)SC 13D/A - Trillium Therapeutics Inc. (0001616212) (Subject)
- SECSEC Form S-8 POS filed by Trillium Therapeutics Inc.S-8 POS - Trillium Therapeutics Inc. (0001616212) (Filer)
- SECSEC Form POSASR filed by Trillium Therapeutics Inc.POSASR - Trillium Therapeutics Inc. (0001616212) (Filer)
TRIL FAQ
7 questionsWhat does Trillium Therapeutics Inc. do?
Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics...Where does TRIL stock trade?
Trillium Therapeutics Inc. (TRIL) is listed on NASDAQ.What sector and industry is TRIL in?
Trillium Therapeutics Inc. operates in the Health Care sector, Major Pharmaceuticals industry.When did Trillium Therapeutics Inc. go public?
Trillium Therapeutics Inc. (TRIL) completed its IPO in n/a.What are analysts saying about TRIL?
Trillium Therapeutics Inc. has had 5 recent analyst actions on file. The most recent action was from The Benchmark Company: Hold on 2021-11-17. Recent price targets cluster around $1850.00.What companies are similar to TRIL?
Notable peers in the same industry include DRNA (Dicerna Pharmaceuticals, Inc.), KDMN (Kadmon Holdings, Inc.), FLXN (Flexion Therapeutics, Inc.), ARPO (Aerpio Pharmaceuticals, Inc.), KIN (Kindred Biosciences, Inc.). Compare TRIL side-by-side with any of them on Quantisnow.How can I track TRIL on Quantisnow?
Quantisnow aggregates Trillium Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TRIL to receive live email and push alerts on every new disclosure.